Magazine Article | April 1, 2016

Companies To Watch: Osel

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Live biotherapeutics to restore microbiomes — in midstage development for vaginal and urinary conditions — with a special focus on women’s health

Osel is both a pioneer and a resurgent player in the microbiome space and in women’s health, with two midstage clinical programs, Lactin-V for bacterial vaginosis and urinary tract infections and CBM588 for antibiotic-associated diarrhea. A third program in HIV prevention uses proprietary mucosal delivery of an engineered virus-fighting bacteria in the vagina. Osel’s products are all “live biotherapeutics,” blazing a new regulatory pathway toward FDA approval.